REGEnLIFE

Name

REGEnLIFE

Legal name

SAS REGEnLIFE

Website

https://regenlife.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others

Revenue model

1. Medical Device Sales: Sale of non-invasive medical devices (REGEnBRAIN for concussion, RGn600 for research) to healthcare facilities, hospitals, and medical practices. The company is preparing for commercialization following CE marking.
2. Clinical Research Services: Making devices available for clinical and preclinical research purposes. Marketing the RGn600 for research purposes as the first medical device targeting brain and gut to treat neuroinflammation.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

REGEnLIFE designs, develops, and manufactures non-invasive medical devices based on patented tri-photonic photobiomodulation (PBM) that combine red and near-infrared light (LEDs and lasers) with a static magnetic field, delivered through a modular helmet and abdominal belt to simultaneously stimulate the brain and gut. Its commercial-stage pipeline includes the RGn600 device marketed for clinical and preclinical research into Alzheimer's and neuroinflammation, and the REGEnBRAIN device for acute concussion treatment that is undergoing CE marking under EU MDR 2017/745.

Product overview

REGEnLIFE is a late-stage medical technology company developing two core products based on its patented tri-photonic photobiomodulation platform: the RGn600 for clinical research targeting Alzheimer's disease through brain-gut stimulation, and REGEnBRAIN for concussion treatment. Both devices use a helmet and abdominal belt to deliver non-invasive light therapy. The company is preparing for market launch with CE marking in progress for REGEnBRAIN.

Differentiator

Problem solved

Functional benefit

Brands

• REGEnBRAIN: Non-invasive medical device for the treatment of concussions using photobiomodulation with red and near-infrared light, currently undergoing CE marking.
• RGn600

Products and services

• REGEnBRAIN

Quantifiable outcome

• Improvement in cognitive functions after just two months of treatment in pilot trial with 50 patients aged 55-85
• +6 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered core.

• RCTs (Clinical Research Organization)coreImplementation/ SI/ Consulting PartnerClinical research organization based in Lyon specializing in the conduct of clinical trials. Partnered with REGEnLIFE to optimize operational monitoring of the Light4Life study and accelerate the launch of the new center at Hospices Civils de Lyon.
• MedValléecoreStrategic or Co-development PartnerMontpellier Méditerranée Métropole initiative supporting Global Health startups. REGEnLIFE selected as winner of Boost Invest MedVallée program, receiving credibility and networking support for fundraising in competitive environment.
• StartUp HealthcoreStrategic or Co-development PartnerMember of StartUp Health Alzheimer's Moonshot Community, providing access to global startup ecosystem, mentorship, and networking opportunities in longevity and Alzheimer's research.
• Hospices Civils de LyoncoreStrategic or Co-development PartnerNew clinical trial site opened at Hôpital des Charpennes under Dr. Antoine Garnier-Crussard for Light4Life pivotal trial. Part of national expansion strategy to accelerate patient recruitment.
• Toulouse University HospitalcoreStrategic or Co-development PartnerLead clinical trial site for Light4Life pivotal trial, led by principal investigator Dr. Julien Delrieu. Also includes Lavaur, Castres, and Foix hospitals in the study network.
• AP-HP (Assistance Publique - Hôpitaux de Paris)coreStrategic or Co-development PartnerLariboisière and Broca hospitals in Paris opened as clinical trial sites in June 2025 for Light4Life pivotal trial, targeting 10 of 108 patients nationally.
• Professor Jacques TouchoncoreStrategic or Co-development PartnerInternational Alzheimer disease specialist and Chair of Scientific Advisory Board at REGEnLIFE. Co-founder of CTAD (Clinical Trials on Alzheimer's Disease). Key scientific advisor and co-author on preclinical and clinical studies.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Vielight: Vielight develops photobiomodulation devices targeting the brain (e.g., Neuro Gamma, Neuro Alpha). It is the most directly comparable company to REGEnLIFE, sharing the PBM modality, transcranial delivery, and focus on cognitive/neurological performance.
• Neuronetics: Neuronetics commercializes NeuroStar, a transcranial magnetic stimulation system for depression and other neurological conditions. Both companies sell non-invasive neurostimulation devices to hospitals and psychiatric clinics, with comparable enterprise GTM motion and indication overlap in depression.
• BrainsWay: BrainsWay develops deep transcranial magnetic stimulation (dTMS) systems for depression, OCD, and smoking cessation. Comparable as a non-invasive brain stimulation medical device company targeting CNS indications through hospital-based channels.
• Magstim: Magstim manufactures transcranial magnetic stimulation equipment used in clinical research and treatment of depression and neurological disorders. Comparable as a non-invasive electromagnetic neurostimulation device vendor serving hospitals and research institutions.
• electroCore: electroCore develops non-invasive vagus nerve stimulation (nVNS) devices for headache, concussion, and inflammatory conditions. Strong functional comparison due to non-invasive neuromodulation modality and overlapping concussion/migraine indications.
• Sooma: Sooma develops transcranial direct current stimulation (tDCS) devices for depression and chronic pain. Comparable as a non-invasive brain stimulation medical device company with a similar clinical-trial-driven go-to-market motion.
• MagVenture: MagVenture is a Danish manufacturer of TMS equipment for psychiatric and neurological research and clinical use. Comparable as a non-invasive electromagnetic neurostimulation device company with similar hospital and research customer base.
• Cerbomed: Cerbomed (now part of Soterix Medical ecosystem) developed transcutaneous auricular vagus nerve stimulation (taVNS) devices for epilepsy and depression. Comparable as a non-invasive neurostimulation company targeting CNS indications.

Broad incumbents

• NeuroPace: NeuroPace commercializes the RNS System, an implantable closed-loop neurostimulator for epilepsy. While implantable rather than non-invasive, it operates in the neurology neuromodulation space and represents a relevant comparable for CNS-targeted neuromodulation medtech.

Emerging players

• MindMaze: MindMaze develops digital therapeutics and brain stimulation platforms for neurological recovery (stroke, traumatic brain injury). Comparable adjacent player in brain-targeted neuromodulation for neurological conditions with overlapping concussion/brain injury use cases.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/regenlife
• Xx.com/regenlife1

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds5 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about REGEnLIFE